May 11, 2020 / 11:46 AM / 13 days ago

BRIEF-Strongbridge Biopharma Announces Completion Of Enrollment Of Phase 3 Logics Study For Recorlev®

May 11 (Reuters) - Strongbridge Biopharma plc:

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 3 LOGICS STUDY FOR RECORLEV® (LEVOKETOCONAZOLE) FOR ENDOGENOUS CUSHING’S SYNDROME

* STRONGBRIDGE BIOPHARMA PLC - LOOK FORWARD TO REPORTING TOP-LINE RESULTS FROM LOGICS STUDY DURING Q3 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below